Financials data is unavailable for this security.
View more
Year on year Shield Therapeutics PLC had net income fall 151.04% from a loss of 19.68m to a larger loss of 49.40m despite a 261.55% increase in revenues from 1.52m to 5.49m.
Gross margin | 44.76% |
---|---|
Net profit margin | -650.12% |
Operating margin | -635.87% |
Return on assets | -109.95% |
---|---|
Return on equity | -140.45% |
Return on investment | -129.39% |
More ▼
Cash flow in GBPView more
In 2022, cash reserves at Shield Therapeutics PLC fell by 13.00m. Cash Flow from Financing totalled 9.37m or 170.59% of revenues. In addition the company used 21.49m for operations while cash used for investing totalled 2.25m.
Cash flow per share | -0.094 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.038 |
---|---|
Tangible book value per share | 0.0166 |
More ▼
Balance sheet in GBPView more
Current ratio | 2.95 |
---|---|
Quick ratio | 2.64 |
Total debt/total equity | 0.213 |
---|---|
Total debt/total capital | 0.1756 |
More ▼